Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancer

• Published in: Experimental and molecular pathology 2023-04, Vol.130, p.104856-104856, Article 104856
• Main Authors: Jasiak, Anna, Koczkowska, Magdalena, Stukan, Maciej, Wydra, Dariusz, Biernat, Wojciech, Izycka-Swieszewska, Ewa, Buczkowski, Kamil, Eccles, Michael R., Walker, Logan, Wasag, Bartosz, Ratajska, Magdalena
• Format: Article
• Language: English
• Subjects: Alternative splicing; Alternative Splicing - genetics; BRCA1; BRCA1 Protein - genetics; BRCA2; BRCA2 Protein - genetics; Breast Neoplasms - genetics; Epithelial ovarian cancer; Female; Genes, BRCA2; Genetic Predisposition to Disease - genetics; Humans; Isoform; Mutation; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; RNA
• ISSN: 0014-4800; 1096-0945
• DOI: 10.1016/j.yexmp.2023.104856

The mRNA splicing is regulated on multiple levels, resulting in the proper distribution of genes' transcripts in each cell and maintaining cell homeostasis. At the same time, the expression of alternative transcripts can change in response to underlying genetic variants, often missed during routine diagnostics. The main aim of this study was to define the frequency of aberrant splicing in BRCA1 and BRCA2 genes in blood RNA extracted from ovarian cancer patients who were previously found negative for the presence of pathogenic alterations in the 25 most commonly analysed ovarian cancer genes, including BRCA1 and BRCA2. Frequency and spectrum of splicing alterations in BRCA1 and BRCA2 genes were analysed in blood RNA from 101 ovarian cancer patients and healthy controls (80 healthy women) using PCR followed by gel electrophoresis and Sanger sequencing. The expression of splicing events was examined using RT-qPCR. We did not identify any novel, potentially pathogenic splicing alterations. Nevertheless, we detected six naturally occurring transcripts, named BRCA1ΔE9-10, BRCA1ΔE11, BRCA1ΔE11q, and BRCA2ΔE3, BRCA2ΔE12 and BRCA2ΔE17-18 of which three (BRCA1ΔE11q, BRCA1ΔE11 and BRCA2ΔE3) were significantly higher expressed in the ovarian cancer cohort than in healthy controls (p ≤ 0.0001). This observation indicates that the upregulation of selected naturally occurring transcripts can be stimulated by non-genetic mechanisms and be a potential systemic response to disease progression and/or treatment. However, this hypothesis requires further examination.